Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment

References

• Alistar, S. S., Grant, P. M., Bendavid, E., Bendavid, E., Holmes, C., Bhattacharya, J., … Hallett, T. (2014). Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Medicine, 12(1), 2060. doi: 10.1186/1741-7015-12-46
   Google Scholar
• Antiretroviral Therapy Cohort Collaboration. (2008). Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet, 372(9635), 293–299. doi: 10.1016/S0140-6736(08)61113-7
   PubMed Web of Science ®Google Scholar
• Cairns, G., McCormack, S., & Molina, J.-M. (2016). The European preexposure prophylaxis revolution. Current Opinion in HIV and AIDS, 11(1), 74–79. doi: 10.1097/COH.0000000000000223
   PubMed Web of Science ®Google Scholar
• Cambiano, V., Miners, A., & Phillips, A. (2016). What do we know about the cost–effectiveness of HIV preexposure prophylaxis, and is it affordable? Current Opinion in HIV and AIDS, 11(1), 56–66. doi: 10.1097/COH.0000000000000217
   PubMed Web of Science ®Google Scholar
• Campillo-Artero, C., Garcia-Armesto, S., & Bernal-Delgado, E. (2016). The merry-go-round of approval, pricing and reimbursement of drugs against the Hepatitis C virus infection in Spain. Health Policy, 120(9), 975–981. doi: 10.1016/j.healthpol.2016.07.005
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). (2015). HIV cost-effectiveness. Retrieved from https://www.cdc.gov/hiv/programresources/guidance/costeffectiveness/index.html
   Google Scholar
• Centre d’Estudis Epidemiològics sobre les Infeccions de Transmissió Sexual i Sida de Catalunya. (2015). Sistema integrat de vigilància epidemiològica de la SIDA/VIH/ITS a Catalunya (SIVES). Barcelona (Spain). Retrieved from http://www.ceeiscat.cat/documents/sives2015.pdf
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP) European Medicines Agency. (2016). Summary of opinion (post authorisation): Truvada (Vol. 1).
   Google Scholar
• Dowson, L., Kober, C., Perry, N., Fisher, M., & Richardson, D. (2012). Why some MSM present late for HIV testing: A qualitative analysis. AIDS Care, 24(2), 204–209. doi: 10.1080/09540121.2011.597711
   PubMed Web of Science ®Google Scholar
• Drabo, E. F., Hay, J. W., Vardavas, R., Wagner, Z. R., & Sood, N. (2016). A cost-effectiveness analysis of pre-exposure prophylaxis for the prevention of HIV among Los Angeles county men who have sex with men. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. doi: 10.1093/cid/ciw578
   PubMed Web of Science ®Google Scholar
• European AIDS Clinical Society (EACS). (2015). EACS Guidelines October 2015. Retrieved from http://www.eacsociety.org/files/guidelines_8.2-english.pdf
   Google Scholar
• European Centre for Disease Prevention and Control, W. R. O. for E. (2015). HIV/AIDS surveillance in Europe 2014. Stockholm, Sweden. Retrieved from http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-in-Europe-2014.pdf
   Google Scholar
• Ferrer, L., Folch, C., Fernandez-Davila, P., Garcia, A., Morales, A., Belda, J., … Casabona, J. (2016). Awareness of pre-exposure prophylaxis for HIV, willingness to use it and potential barriers or facilitators to uptake among men who have sex with men in Spain. AIDS and Behavior, 20(7), 1423–1433. doi: 10.1007/s10461-016-1379-9
   PubMed Web of Science ®Google Scholar
• Ferrer, L., Loureiro, E., Meulbroek, M., Folch, C., Perez, F., Esteve, A., … Casabona, J. (2015). High HIV incidence among men who have sex with men attending a community-based voluntary counselling and testing service in Barcelona, Spain: Results from the ITACA cohort. Sexually Transmitted Infections. doi: 10.1136/sextrans-2015-052042
   PubMed Web of Science ®Google Scholar
• Forsyth, A. D., & Valdiserri, R. O. (2012). Reaping the prevention benefits of highly active antiretroviral treatment: policy implications of HIV Prevention Trials Network 052. Current Opinion in HIV and AIDS. doi: 10.1097/COH.0b013e32834fcff6
   PubMed Web of Science ®Google Scholar
• Frankis, J., Young, I., Flowers, P., McDaid, L., & Dezzutti, C. S. (2016). Who will use Pre-Exposure Prophylaxis (PrEP) and why?: Understanding PrEP awareness and acceptability amongst men who have sex with men in the UK – A mixed methods study. PloS One, 11(4), e0151385. doi: 10.1371/journal.pone.0151385
   PubMed Web of Science ®Google Scholar
• Generalitat de Catalunya. (n.d.). Servei Català de la Salut (CatSalut). Retrieved from http://catsalut.gencat.cat/ca/inici/
   Google Scholar
• Gomez, G. B., Borquez, A., Caceres, C. F., Segura, E. R., Grant, R. M., Garnett, G. P., & Hallett, T. B. (2012). The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: A mathematical modelling study. PLoS Medicine, 9(10), e1001323. doi: 10.1371/journal.pmed.1001323
   PubMed Web of Science ®Google Scholar
• Gomez, G. B., Borquez, A., Case, K. K., Wheelock, A., Vassall, A., & Hankins, C. (2013). The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: A systematic review of cost-effectiveness modelling studies. PLoS Medicine. doi: 10.1371/journal.pmed.1001401
   Web of Science ®Google Scholar
• Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., … Glidden, D. V. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine, 363(27), 2587–2599. doi: 10.1056/NEJMoa1011205
   PubMed Web of Science ®Google Scholar
• Grupo de Estudio de Sida de la SEIMC (GeSIDA). (2016). Recomendaciones sobre Profilaxis Pre-Exposición en adultos para la Prevención de la Infección por VIH en España. Retrieved from http://www.gesida-seimc.org/contenidos/guiasclinicas/2016/gesida-guiasclinicas-2
   Google Scholar
• Hankins, C., Macklin, R., & Warren, M. (2015). Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access. Journal of the International AIDS Society, 18(4 (Suppl 3)), doi: 10.7448/IAS.18.4.19973
   PubMedGoogle Scholar
• Lim, S. S., Allen, K., Bhutta, Z. A., Dandona, L., Forouzanfar, M. H., Fullman, N., … Murray, C. J. L. (2016). Measuring the health-related sustainable development goals in 188 countries: A baseline analysis from the global burden of disease study 2015. The Lancet, 388(10053), 1813–1850. doi: 10.1016/S0140-6736(16)31467-2
   PubMed Web of Science ®Google Scholar
• Marcus, U., Hickson, F., Weatherburn, P., & Schmidt, A. J. (2013). Estimating the size of the MSM populations for 38 European countries by calculating the survey-surveillance discrepancies (SSD) between self-reported new HIV diagnoses from the European MSM internet survey (EMIS) and surveillance-reported HIV diagnoses among MSM in 2009. BMC Public Health, 13(1), 1365. doi: 10.1186/1471-2458-13-919
   Google Scholar
• McCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., … Gill, O. N. (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): Effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet, 387(10013), 53–60. doi: 10.1016/S0140-6736(15)00056-2
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad Servicios Sociales e Igualdad. (2009). Resumen Ejecutivo de la Encuesta Nacional de Salud Sexual (2009).
   Google Scholar
• Ministerio de Sanidad Servicios Sociales e Igualdad. (2014). Plan Nacional sobre el Sida S.G. de Promoción de la Salud y Epidemiología/Centro Nacional de Epidemiología-ISCII. Madrid (Spain). Retrieved from https://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/PlanEstrategico2013_2016.pdf
   Google Scholar
• Molina, J.-M., Capitant, C., Charreau, I., Meyer, L., Spire, B., Pialoux, G., … Tremblay, C. (2015). On demand PrEP with oral TDF-FTC in MSM: Results of the ANRS Ipergay trial. Conference on Retroviruses and Opportunistic Infections (CROI). Retrieved from http://www.mendeley.com/catalog/demand-prep-oral-tdfftc-msm-results-anrs-ipergay-trial/
   Google Scholar
• Nakagawa, F., Miners, A., Smith, C. J., Simmons, R., Lodwick, R. K., Cambiano, V., … Phillips, A. N. (2015). Projected lifetime healthcare costs associated with HIV infection. PloS One, 10(4), e0125018. doi: 10.1371/journal.pone.0125018
   PubMed Web of Science ®Google Scholar
• Ndawinz, J. D. A., Costagliola, D., & Supervie, V. (2011). New method for estimating HIV incidence and time from infection to diagnosis using HIV surveillance data: Results for France. AIDS, 25(15), 1905–1913. doi: 10.1097/QAD.0b013e32834af619
   PubMed Web of Science ®Google Scholar
• Ong, K. J., Desai, S., Desai, M., Nardone, A., van Hoek, A. J., & Gill, O. N. (2015). Cost and cost-effectiveness of an HIV pre-exposure prophylaxis (PrEP) programme for high-risk men who have sex with men in England: Results of a static decision analytical model. The Lancet, 386, S16. doi: 10.1016/S0140-6736(15)00854-5
   PubMedGoogle Scholar
• Ouellet, E., Durand, M., Guertin, J. R., LeLorier, J., & Tremblay, C. L. (2015). Cost effectiveness of “on demand” HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. Canadian Journal of Infectious Diseases and Medical Microbiology, 26(1), 23–29. doi: 10.1155/2015/964512
   PubMed Web of Science ®Google Scholar
• Paltiel, A. D., Freedberg, K. A., Scott, C. A., Schackman, B. R., Losina, E., Wang, B., … Walensky, R. P. (2009). HIV preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 48(6), 806–815. doi: 10.1086/597095
   PubMed Web of Science ®Google Scholar
• Phillips, A. N., Cambiano, V., Miners, A., Lampe, F. C., Rodger, A., Nakagawa, F., … Delpech, V. (2015). Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. AIDS, 29(14), 1855–1862. doi: 10.1097/QAD.0000000000000767
   PubMed Web of Science ®Google Scholar
• Plan Nacional sobre el Sida S.G. de Promoción de la Salud y Epidemiología/Centro Nacional de Epidemiología-ISCII. (2016). Grupo EPI-VIH. Estudio prospectivo de prevalencia de VIH en personas atendidas en una red de centros específicos de VIH/ITS, 2000–2013. Madrid: Centro Nacional de Epidemiología.
   Google Scholar
• Punyacharoensin, N., Edmunds, W. J., De Angelis, D., Delpech, V., Hart, G., Elford, J., … White, R. G. (2014). Modelling the HIV epidemic among MSM in the United Kingdom. AIDS, 29(3), 1. doi: 10.1097/QAD.0000000000000525
   Web of Science ®Google Scholar
• Punyacharoensin, N., Edmunds, W. J., De Angelis, D., Delpech, V., Hart, G., Elford, J., … White, R. G. (2016). Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: A mathematical modelling study. The Lancet HIV, 3(2), e94–e104. doi: 10.1016/S2352-3018(15)00056-9
   PubMed Web of Science ®Google Scholar
• Ratmann, O., van Sighem, A., Bezemer, D., Gavryushkina, A., Jurriaans, S., Wensing, A., … Fraser, C. (2016). Sources of HIV infection among men having sex with men and implications for prevention. Science Translational Medicine, 8(320), 320ra2. doi: 10.1126/scitranslmed.aad1863
   PubMed Web of Science ®Google Scholar
• Rivero, A., Pérez-Molina, J. A., Blasco, A. J., Arribas, J. R., Crespo, M., Domingo, P., … Gatell, J. M. (2016). Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiología Clínica, (xx). doi: 10.1016/j.eimc.2016.06.013
   Google Scholar
• Ross, E. L., Cinti, S. K., & Hutton, D. W. (2016). Implementation and operational research: a cost-effective, clinically actionable strategy for targeting HIV preexposure prophylaxis to high-risk men who have sex with men. JAIDS Journal of Acquired Immune Deficiency Syndromes, 72(3), e61–e67. doi: 10.1097/QAI.0000000000000987
   PubMed Web of Science ®Google Scholar
• Sorensen, S. W., Sansom, S. L., Brooks, J. T., Marks, G., Begier, E. M., Buchacz, K., … Colizza, V. (2012). A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States. PLoS ONE, 7(2), e29098, doi: 10.1371/journal.pone.0029098
   PubMed Web of Science ®Google Scholar
• Tengs, T. O., & Lin, T. H. (2002). A meta-analysis of utility estimates for HIV/AIDS. Medical Decision Making, 22(6), 475–481. doi: 10.1177/0272989X02238300
   PubMed Web of Science ®Google Scholar
• Trapero-Bertran, M., & Oliva-Moreno, J. (2014). Economic impact of HIV/AIDS: A systematic review in five European countries. Health Economics Review, 4(1), 1046. doi: 10.1186/s13561-014-0015-5
   Google Scholar
• Trueman, P., Drummond, M., & Hutton, J. (2001). Developing guidance for budget impact analysis. PharmacoEconomics, 19(6), 609–621. doi: 10.2165/00019053-200119060-00001
   PubMed Web of Science ®Google Scholar
• van Sighem, A., Nakagawa, F., De Angelis, D., Quinten, C., Bezemer, D., de Coul, E. O., … Phillips, A. (2015). Estimating HIV incidence, time to diagnosis, and the undiagnosed HIV epidemic using routine surveillance data. Epidemiology, 26(5), 653–660. doi: 10.1097/EDE.0000000000000324
   PubMed Web of Science ®Google Scholar
• Weatherburn, P., Schmidt, A. J., Hickson, F., Reid, D., Berg, R. C., Hospers, H. J., & Marcus, U. (2013). The European men-who-have-sex-with-men internet survey (EMIS): Design and methods. Sexuality Research and Social Policy, 10(4), 243–257. doi: 10.1007/s13178-013-0119-4
   Web of Science ®Google Scholar